India’s weight-loss story is no longer just about gyms and diets; it’s showing up in pharma sales. In five years, it has grown sixfold to cross $100 million in FY25. Rising obesity and diabetes are driving demand, even as high costs limit access. With patent expiries ahead and local manufacturing gearing up, the big question is: can this shift from premium niche to mass-market healthcare story?